1	Full Title: Factors associated with SARS-CoV-2 among persons living with HIV in Zambia:
2	Analysis of three concurrent SARS-CoV-2 prevalence surveys conducted in July 2020 in six
3	districts of Zambia
4	Short Title: SARS-CoV-2 Prevalence and Associated Factors Among Persons Living with HIV
5	in Zambia: July 2020
6	
7	Stephen Longa Chanda ^{1,2} , Cephas Sialubanje ² , Mukumbuta Nawa ² , Nyambe Sinyange ¹ , Warren Malambo ³ , James Zulu ¹ , Dabwitso Banda ¹ , Paul Zulu ¹ , Jonas Hines ³
9	
10	1. Zambia National Public Health Institute, Surveillance and Disease Intelligence Cluster,
11	Lusaka Zambia
12	2. School of Public Health, Department of Environmental and Public Health, Levy
13	Mwanawasa Medical University, Lusaka, Zambia
14	3. United States Centers for Disease Control and Prevention, Lusaka, Zambia
15	4. Ministry of Health, Lusaka, Zambia
16	
17	Corresponding Author
18	Stephen Longa Chanda
19	Physical address: Zambia National Public Health Institute, Corner of Chaholi and Addis
20	Ababa Road, Rhodespark, Lusaka
21	Phone number: +260973721052
22	email address- longachandadoc88@gmail.com

23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Author contributions

- 25 Stephan Longa Chanda was the principal investigator.
- 26 Stephen Longa Chanda, Cephas Sialubanje, Mukumbuta Nawa, Nyambe Sinyange, Warren
- 27 Malambo, James Zulu, Dabwitso Banda1, Paul Zulu1, Lloyd B. Mulenga and Jonas Hines designed

the study.

- Warren Malambo, Nyambe Sinyange, James Zulu, Dabwitso Banda, and Jonas Hines collected thedata.
- 31 Stephan Chanda, and Jonas Z Hines analysed the data.

Stephen Longa Chanda, Cephas Sialubanje, Mukumbuta Nawa, Nyambe Sinyange, Warren
Malambo, James Zulu, Dabwitso Banda, Paul Zulu, Lloyd B. Mulenga, Jonas Hines wrote the
manuscript.

35

- 37 Keywords
- 38 HIV infections, SARS-CoV-2, prevalence, reverse transcriptase polymerase chain reaction, enzyme-
- 39 linked immunosorbent assay, Zambia, COVID-19 vaccines
- 40
- 41
- 42

43 Abstract

People living with HIV (PLHIV) are a unique population because of their altered immune systems and taking antiretroviral therapy (ART) that may modify risk of SARS-CoV-2. Evidence from sub-Saharan African countries suggests that, despite not having higher SARS-CoV-2 infection prevalence than HIV-negative persons, PLHIV suffer worse COVID-19 outcomes. We assessed the prevalence of SARS-COV-2 infection by HIV status in Zambia in July 2020.

We analyzed data from three different concurrent SARS-CoV-2 prevalence surveys (household, 49 outpatient-department, and health-worker) conducted in six districts of Zambia in July 2020. 50 Information on demographics and medical history was collected. Nasopharyngeal swabs were used 51 to screen for SARS-CoV-2 RNA using polymerase-chain-reaction (PCR) and blood specimens were 52 screened for SARS-CoV-2 virus-specific antibodies using an enzyme-linked-immunosorbent-assay 53 (ELISA). Test-specific SARS-CoV-2 prevalence was calculated. Multilevel logistic regression 54 models were used to measure test-specific adjusted odd ratios (aORs) of SARS-CoV-2 positivity by 55 HIV status, controlling for demographic and medical history. 56

57 We analysed the outcomes of the two different tests separately. Among 7,092 participants, 4,717 (66.5%) consented to blood-draw and 4,642 (65.5%) consented to nasopharyngeal swab. Overall 58 SARS-CoV-2 positivity was 9.4% by PCR and 3.8% by ELISA. SARS-CoV-2 prevalence detected 59 by PCR was higher among PLHIV than HIV-negative respondents (12.4% vs 9.1%, respectively, OR: 60 1.4, 95% confidence intervals [CI]: 1.0-1.9) and lower by ELISA (1.9% vs 3.9%, respectively, OR: 61 0.5, 95%CI: 0.2-0.9). Among PLHIV, not being on ART was an independent predictor of SARS-62 CoV-2 PCR positivity (aOR: 5.24,95% CI: 1.19-22.22) but did not have a significant effect on ELISA 63 results. 64

During the first COVID-19 wave in Zambia, PLHIV were more likely to be acutely infected with
 SARS-CoV-2 but less likely to be seropositive than participants without HIV. Intervention programs
 could focus on early access to COVID-19 vaccinations, testing and ART might reduce COVID-19
 morbidity among PLHIV.

69 Word count: 294

70 Introduction

From March 2020 through January 2023, over 339,000 laboratory-confirmed cases of SARS-CoV-2 infections and over 4,000 deaths were reported in Zambia (1). Lusaka, the national capital, reported the highest number of cases (77%), with 61% of cases reported among men and more than one-third (32%) of cases involving adults aged 30-44 years (2). Elderly patients (aged >60 years) and those with comorbidities (e.g., HIV, chronic lung disease, hypertension, diabetes, cardiovascular disease, and chronic kidney disease) are at high risk of severe infection and mortality (3,4). Immunosuppression has also been associated with more severe outcomes (5).

HIV remains one of the biggest public health problems globally, with approximately 38.4 million
people living with HIV (PLHIV) globally in 2021 and over 650 000 deaths from AIDS-related
illnesses in 2021 (6). The HIV epidemic continues to impact a large portion of Zambian adults, with
an HIV prevalence of 9.9 (95% CI: 9.1-10.7) among adults aged 15-59 years in 2021 [4].

Current evidence shows that due to aberrant humoral and T-cell-mediated immune responses, PLWH 82 83 have a higher susceptibility to other infections, such as respiratory infections (7). As more PLHIV age (8), the prevalence of age-related comorbidities among them increases along with the associated 84 risk of severe COVID-19 outcomes. PLHIV with COVID-19 may have more severe clinical 85 presentations and outcomes. The increased risk of SARS-CoV-2 infection or severe disease among 86 87 PLHIV may be due to immune dysregulation because of CD8-T lymphocyte cell exhaustion (9). T-88 cell exhaustion occurs secondary to persistently high levels of HIV viral antigen, which leads to strong proinflammatory immune activation and compromised T-cell homeostasis (7). In addition to this HIV-89 induced immune dysregulation, coronaviruses have been shown to cause transient immune 90 91 deficiencies that could further weaken the immune system in an already immunocompromised host (10-12). On the other hand, HIV-associated immunosuppression could help temper the cytokine 92 storm of COVID-19 and thus protect against severe forms of COVID-19 (13). In addition, PLHIV on 93

combined antiretroviral treatment (cART) might have a modified risk of infection and a different
clinical course of COVID-19 than those not on treatment, as some antiretrovirals may have theoretical
activity against SARS-CoV-2 (14–16).

Studies conducted early in the pandemic in the United States of America and Europe showed no 97 difference in the clinical presentation, hospital course and outcomes of COVID-19 between PLHIV 98 and HIV-negative adults (17-20). However, newer evidence from a systematic review and meta-99 analysis (21), several cohort studies (22-24) and case series (25-27) have shown that PLHIV have a 100 higher risk of severe COVID-19 (hospitalisation, admission to the intensive care unit (ICU), 101 intubation or mechanical ventilation, or death). These studies included PLHIV with suppressed viral 102 loads and different demographic characteristics and comorbidities compared to PLHIV in Africa 103 (9,28,29). The systematic review and meta-analysis conducted by Ssentongo et al in 2021 comprising 104 22 studies that included over 20 million participants across North America, Africa, Europe, and Asia 105 established that PLHIV had a 24% greater risk of SARS-CoV-2 infection (1.24, 95% [CI 1.05-1.46]) 106 than HIV-negative individuals (21). However, the only African country included in this review was 107 South Africa, one of the most developed economies on the continent. In this meta-analysis, ART 108 (tenofovir and protease inhibitors) did not reduce the risk of SARS-CoV-2 infection or death from 109 COVID-19 among PLHIV (21). In this meta-analysis, most respondents had controlled HIV infection 110 (median CD4 count was 538 cells/µL, and 80% of the PLHIV patients were virally suppressed [than 111 50 copies of HIV/mL]), and over 96% of PLHIV were on ART(21). In South Africa, a seroprevalence 112 survey among both PLHIV and HIV-negative antenatal women showed that PLHIV had a higher 113 SARS-CoV-2 seroprevalence than antenatal HIV-negative women (30). A prospective cohort study 114 conducted in South Africa showed that PLHIV who were not virally suppressed were more likely to 115 develop symptomatic illness when infected with SAR-CoV-2 (OR 3.3 [95% CI 1.3-8.4]) and shed 116 SARS-CoV-2 for longer (hazard ratio 0.4 [95% CI 0.3-0.6]) compared with HIV-uninfected 117 individuals (31). 118

Several seroprevalence surveys of SARS-CoV-2 antibody and HIV testing in the general population 119 have shown that PLHIV are less likely to be seropositive than HIV-uninfected individuals (32–35). 120 In these surveys, poor HIV control (evidenced by either high viral load, low CD4 count or not yet on 121 ART) was associated with a poorer antibody response to SARS-CoV-2 infection (32-35). A cross-122 sectional SARS-CoV-2 seroprevalence survey conducted in Zambia found no association between 123 SARS-CoV-2 antibody seroprevalence and HIV status (36). As this study was limited to only Kabwe 124 125 District, the findings of this study may not be generalizable to the rest of the country. The lower seroprevalence rates among PLHIV could be due to HIV-induced impaired humoral response, as HIV 126 127 targets CD4+ T lymphocytes. CD4+ T cells are pivotal in orchestrating both the humoral and cellular immune responses to vaccination and prior infections and have an important role in antibody 128 production (37). 129

130 In sub-Saharan Africa, including Zambia, there is a growing body of evidence on coinfection between HIV and COVID-19 with regional differences. Moreover, Zambia has a large population of PLHIV, 131 whose demographic composition and comorbidity profile are different from most of the populations 132 on which the current literature on COVID-19 in PLHIV is based. The aim of this study was to compare 133 the SARS-CoV-2 test positivity, clinical presentation, and predictors of test-specific SARS-CoV-2 134 positivity between PLHIV and people who are HIV negative in six districts of Zambia. Information 135 is needed to inform policy and interventions focusing on reducing COVID-19 morbidity among 136 137 PLHIV.

139 Materials and Methods

140 Study design

We used secondary de-identified data from three different SARS-CoV-2 prevalence surveys conducted in six districts during the upswing of Zambia's first COVID-19 wave in July 2020. These datasets were made available upon request from the MOH on the 21st of December 2021.

144 Study setting

The study was conducted in six out of the 116 districts of Zambia (Lusaka, Ndola, Livingstone, Kabwe, Nakonde and Solwezi) across six provinces (Lusaka, Copperbelt, Southern, Central, Muchinga and North-western) of Zambia. These districts were purposively selected due to high SARS-CoV-2 prevalence, being major gateways or transport hubs and to ensure adequate urban rural disaggregation.

150 Study participants

Participants in the three surveys included community members from the selected districts, who were drawn from a cross-sectional cluster-sample survey of households in the six districts of Zambia. Within each district, 16 standardised enumeration areas were randomly selected as primary sampling units using probability proportional to size. All households within each standardised enumeration area were listed, and 20 households from each standardised enumeration area were selected using simple random sampling: people seeking care at outpatient departments (OPDs) in the selected health facilities within these districts and healthcare workers (HCWs) in these same facilities.

158 Inclusion criteria

Only individuals (of any age) who had slept in the house the night before the survey was done were eligible to participate in the household survey. In the outpatient survey, participants were randomly selected from all the patients attending 20 conveniently selected outpatient clinics at hospitals and health centres in the six districts. HCWs were selected from the same 20 health facilities (HFs) conveniently selected in the outpatient survey in the six districts. A convenience sample of HCWs at
the selected HFs who were present during the survey dates were recruited. For smaller HFs (e.g.,
health centres), all HCWs were included; for larger HFs (e.g., hospitals), 50 HCWs were invited to
participate.

167 Sampling technique and sample size estimation

As our study used secondary data, there was no a priori sample size calculation. Participants could 168 accept either PCR or ELISA or both, and we analysed the outcomes of the two different tests 169 separately. For the analysis of overall SARS-CoV-2 PCR test positivity and seropositivity, we used 170 all respondents who took the respective test modality. For the comparison of symptoms reported at 171 enrolment (during survey administration?) Once infected with SARS-CoV-2, we only used the subset 172 of respondents who had a positive PCR test. For the determination of factors associated with SARS-173 CoV-2 positivity among PLHIV, we used all the PLHIV who accepted either test modality (Figure 174 1). 175

To determine if the sample used in our analysis for predictors of SARS-CoV-2 positivity had enough
statistical power to make an inference, the sample size by test type was calculated using the following
formula.

179 $n=p*Z^{2*}(1-p)/E^2$ 180where181n is the required sample size182P is the percentage occurrence of a state or condition183E is the percentage maximum error required184Z is the value corresponding to the level of confidence required

185

186 With 4642 respondents who were tested by PCR only, the minimum sample size needed for the study
187 to have 80% power is 259; the study therefore has enough power to make statistically significant
188 inferences.

With 4717 respondents who were tested by ELISA only, the minimum sample size needed for the study to have 80% power is 76; the study therefore has enough power to make statistically significant inferences.

192 Variables

193 Outcome variable

The outcome variable was SARS-CoV-2 positivity. Participants could be tested by PCR, ELISA, or both. We analysed the two different outcomes separately (PCR and ELISA). PCR and ELISA results were used to determine test-specific positivity and factors associated with being SARS-CoV-2 positive. For the analysis of symptomology, we only used the subset of respondents who had a positive PCR test.

199 Independent variables

The independent variables were demographic characteristics (age, sex) and self-reported medical history (tuberculosis, malaria, diabetes, cardiac disease, hypertension, asthma, chronic obstructive pulmonary disease, chronic kidney disease, liver disease, cancer, any other past medical history). SARS-CoV-2 exposure was defined as any history in the one month prior to testing of household contact with a confirmed case of COVID-19, social contact with a confirmed case of COVID-19, domestic or international travel, in-person attendance to workplace/school/daycare, visit to a health care facility, number of visits to market/grocer and usual means of transportation.

207 Data collection procedures

Data on independent variables were collected through administration of a standardised questionnaire 208 by trained personnel that included information about demographics, self-reported medical history 209 210 including symptomatology prior to testing, and SARS-CoV-2 exposure history. Next, the specimen for the PCR test was collected by using nasopharyngeal swabs (1 per participant) collected into a 211 212 cryovial with viral transport medium for detection of SARS-CoV-2 RNA using real-time reverse transcription PCR (38). Additionally, blood samples were collected by finger prick using the BD 213 microtainer EDTA cryovial tube system for detection of anti-spike protein IgG SARS-CoV-2 214 215 antibodies using Euroimmun ELISA (PerkinElmer, Waltham, MA, USA) in single replicate according to the manufacturer's instructions (39). 216

217 Data management and analysis

218 All statistical analyses were performed using R statistical software (40). Data from the three surveys were merged for analysis. We then assessed for completeness and missingness by running frequency 219 220 tables and cross-tabulations of all variables. Due attention was given to skip patterns before using multiple imputations using chained equations using the MICE package in R statistical software to 221 impute values for variables with equal to or less than five percent missing values. Variables with 222 greater than five percent missingness were dropped from subsequent analysis. We then performed 223 diagnostic analyses to identify sample distribution and outliers to guide subsequent statistical tests. 224 225 The continuous variable age was recoded into a categorical variable age group. A logical variable "any symptom" was recoded from the variable symptom, with two levels, "true or false". If true, the 226 respondent presented with at least one symptom. Similarly, another logical variable, "any comorbid", 227 228 was recoded from those respondents who had reported at least one comorbid medical condition excluding HIV, which was analysed separately. 229

SARS-CoV-2 positivity was calculated as the number of positive results divided by the total number 230 of tests performed (for a given test modality). PCR and ELISA positivity estimates were reported 231 232 separately. Descriptive statistics were used to summarise participant characteristics. Stratified analysis was used to compare self-reported HIV status-specific positivity rates. The Shapiro-Wilk 233 test was used to determine the distribution of continuous variables. Pearson chi-square and Fisher's 234 exact tests were used to determine associations between the independent and outcome variables. 235 236 Wilcoxon rank sum tests were used to determine the difference in the medians for continuous variables between PLHIV and HIV-negative participants. 237

Multilevel logistic regression was used to determine the factors associated with SARS-CoV-2 238 positivity among PLWH by PCR and ELISA as well as the strength of association. To account for the 239 spatial clustering of participants in each of the six districts, we assumed a random intercept; that is, 240 each of the 6 districts had its unique intercept. In contrast, we assumed fixed effects for all other 241 covariates (that is, an estimated mean effect for the 6 districts). Variables controlled for included age, 242 243 ART use, sex, visit to a health facility, in-person attendance at a workplace, school or day care and the presence of any comorbid medical condition. Investigator-led stepwise elimination was used to 244 derive the final model using the AIC and BIC values for each test modality until all predictors had a 245 p value of 0.5 or less. Adjusted odds ratios and their 95% confidence intervals (CIs) (p<0.05) were 246 computed. 247

248 Ethical considerations

The study was conducted under the public health response authority from the Ministry of Health; therefore, permission from the Permanent Secretary, Technical Services at the Ministry of Health was obtained to access the data currently held at the MOH. The study used secondary data and did not involve any interaction with human subjects. The data were deidentified and kept secure. No names of participants were obtained. The data set was handled with confidentiality and only used for the purposes of this study. The data were not subject to undue prejudice. Ethical approval to conduct the study was obtained from the ERES converge ethical review board (Ref. No 2021-November-010),
and research authority was obtained from the National Health Research Authority (NHRA316/06/10/2022).

258 Results

259 Participants

A summary of the recruitment algorithm of study participants from the different primary studies is 260 261 shown in Figure 1A. A total of 7,328 respondents were approached in all three studies, with most respondents from the household survey (64%) (Figure 1A). A total of 7,092 (96.6%) participants 262 agreed to participate in the respective surveys: 4469 (95.3%) completed the household survey, 1,952 263 (98.3%) completed the OPD survey and 660 (99.5%) completed the HCW survey (Figure 1A). A total 264 of 5938 (83.7%) of the participants approached consented to SARS-CoV-2 testing. With 4717 265 (79.4%) tested by ELISA, 4642 (78.2%) tested by PCR, and 3421 (57.6%) tested by both test 266 267 modalities (Figure 1B), we did not analyse those tested by both test modalities separately.

Figure 1A: Summary of the study participant recruitment algorithm by study type

Figure 1B: Outline of the algorithm of the selection of study participants into the different arms ofthe study

271

272 Demographic characteristics of study participants

The median age among all participants who consented to take part in the study was 28.0 years (IQR: 273 19.0-41.0). More female participants (61.6%) were enrolled, and most participants had attended 274 secondary education (37.9%) and did not have any comorbid medical conditions (82.0%). In the entire 275 sample, the HIV prevalence was 8.8 percent, and among those who were HIV positive, only 2.4 276 percent were not on ART (Table 1). Most respondents came from Lusaka district (23.8%), followed 277 by Solwezi district (18.2%), with the least number of respondents from Nakonde district (10.6%) 278 (Table 1). The demographic characteristics of respondents who were tested by either PCR or ELISA 279 were similar to those from the overall sample (Table 1). The demographic characteristics of those 280

- tested by PCR or ELISA were similar (Table 1). Compared to HIV-negative study participants,
- PLHIV were older (median ages: 42 years versus 27 years, p value < 0.001), and a greater proportion
- had at least one comorbidity other than HIV (44.5% versus 16.7%, p value < 0.001) (Table 2).

		Tested by	Tested by PCR
	Overall (N= 7092)	ELISA ¹	(N=4642), n
Variable	n (%)	(N=4717), n (%)	(%)
Sex			
Male	2716 (38.4)	1786 (37.9)	1854 (39.9)
Female	4352 (61.6)	2931 (62.1)	2788 (60.1)
Missing	24		
Age, years			
median			
(IQR ³)	28.0 [19.0;41.0]	29.0 [21.0;42.0]	28.0 [19.0;41.0]
Age group,			
years			
<19	1842 (26.1)	1009 (21.4)	1231 (26.5)
20-29	1926 (27.3)	1378 (29.2)	1224 (26.4)
30-39	1395 (19.8)	984 (20.9)	919 (19.8)
40-49	847 (12.0)	593 (12.6)	549 (11.8)
50-59	548 (7.8)	397 (8.4)	374 (8.1)
>60	495 (7.0)	356 (7.5)	345 (7.4)
Missing	39		
Education			
Primary	2221 (32.0)	1393 (29.5)	1399 (30.1)
Secondary	2632 (37.9)	1863 (39.5)	1816 (39.1)
Higher	1608 (23.2)	1231 (26.1)	1111 (23.9)
None	485 (7.0)	230 (4.9)	316 (6.8)
Missing	146		
Any			
Comorbidity			
No	5815 (82.0)	3806 (80.7)	3751 (80.8)
Yes	1277 (18.0)	911 (19.3)	891 (19.2)
HIV			
No	5853 (91.2)	4243 (90.0)	4222 (91.0)
Yes	565 (8.8)	474 (10.0)	420 (9.0)
Missing	674		
On ART			

Table 1. Demographic characteristics of study participants tested for SARS-CoV-2 infection, 6
 districts, Zambia, July 2020

Yes	537 (97.6)	407 (97.8)	365 (97.9)			
No	13 (2.4)	9 (2.2)	8 (2.1)			
NA	6542	4301	4269			
Survey						
Outpatient	1952 (27.6)	1576 (33.4)	1395 (30.1)			
Household	4469 (63.1)	2616 (55.5)	2823 (60.8)			
Healthcare						
worker	660 (9.3)	525 (11.1)	424 (9.1)			
Missing	11					
District						
Lusaka	1690 (23.8)	1152 (24.4)	977 (21.0)			
Livingstone	1134 (16.0)	836 (17.7)	781 (16.8)			
Nakonde	753 (10.6)	499 (10.6)	308 (6.6)			
Ndola	1234 (17.4)	979 (20.8)	975 (21.0)			
Kabwe	987 (13.9)	582 (12.3)	657 (14.2)			
Solwezi	1294 (18.2)	669 (14.2)	944 (20.3)			
	1 PCR: polymerase chain reaction, 2 ELISA: -enzyme-linked immunosorbent assay, 3 Combination of either ELISA and PCR positive and ELISA or PCR negative, 4 HCW: healthcare worker.					

287	Table 2. Demographic characteristics of respondents stratified by HIV status and SARS-CoV-2 test
288	type.

	Te	Tested by PCR			Tested by ELISA		
		HIV status		HIV status			
	Negative (N=4222)	Positive (N=420)		Negative (N=4254)	Positive (N=463)		
<u>a</u> 1	n (%)	n (%)	p value	n (%)	n (%)	p value	
Sex ¹			0.0004			0.0004	
Male	1720 (40.7)	134 (31.9)		1646 (38.7)	140 (30.2)		
Female	2502 (59.3)	286 (68.1)		2608 (61.3)	323 (69.8)		
Age ²			< 0.0001			< 0.0001	
	27.0	42.0		28.0	42.0		
Median (IQR)	[18.0;39.0]	[34.0;51.0]		[20.0;40.0]	[35.0;50.0]		
Age group ¹			< 0.0001			< 0.0001	
<19	1221 (28.9)	10 (2.4)		1001 (23.5)	8 (1.7)		
20-29	1166 (27.6)	58 (13.8)		1319 (31.0)	59 (12.7)		
30-39	812 (19.2)	107 (25.5)		859 (20.2)	125 (27.0)		
40-49	422 (10.0)	127 (30.2)		448 (10.5)	145 (31.3)		
50-59	305 (7.2)	69 (16.4)		321 (7.5)	76 (16.4)		
>60	296 (7.0)	49 (11.7)		306 (7.2)	50 (10.8)		

Education completed ¹			0.0021			0.0003
Primary	1281 (30.3)	118 (28.1)		1245 (29.3)	148 (32.0)	
Secondary	1620 (38.4)	196 (46.7)		1652 (38.8)	211 (45.6)	
Higher	1021 (24.2)	90 (21.4)		1147 (27.0)	84 (18.1)	
None	300 (7.1)	16 (3.8)		210 (4.9)	20 (4.3)	
Any comorbidities ¹			< 0.0001			< 0.0001
No	3518 (83.3)	233 (55.5)		3529 (83.0)	277 (59.8)	
Yes	704 (16.7)	187 (44.5)		725 (17.0)	186 (40.2)	
PCR result ¹			0.0277			0.0311
Negative	3838 (90.9)	368 (87.6)		4086 (96.1)	454 (98.1)	
Positive	384 (9.1)	52 (12.4)		168 (3.9)	9 (1.9)	
On ART			NA			NA
Yes		365 (97.9)			407 (97.8)	
No		8 (2.1)			9 (2.2)	
Missing		47			47	
Survey ¹			< 0.0001			< 0.0001
Outpatient	1202 (28.5)	193 (46.0)		1354 (31.8)	222 (47.9)	
Household	2621 (62.1)	202 (48.1)		2405 (56.5)	211 (45.6)	
Healthcare worker	399 (9.5)	25 (6.0)		495 (11.6)	30 (6.5)	
District ¹			< 0.0001			< 0.0001
Lusaka	903 (21.4)	74 (17.6)		1040 (24.4)	112 (24.2)	
Livingstone	699 (16.6)	82 (19.5)		745 (17.5)	91 (19.7)	
Nakonde	289 (6.8)	19 (4.5)		471 (11.1)	28 (6.0)	
Ndola	868 (20.6)	107 (25.5)		872 (20.5)	107 (23.1)	
Kabwe	552 (13.1)	105 (25.0)		490 (11.5)	92 (19.9)	
Solwezi	911 (21.6)	33 (7.9)		636 (15.0)	33 (7.1)	
Solwezi ¹ Pearson-Chi-square, ² Wilcoxor	()	33 (7.9)		636 (15.0)	33 (7.1)	

290 SARS-CoV-2 positivity

291	Among all participants, SARS-CoV-2 positivity was 9.4% and 3.8% by PCR and ELISA,
292	respectively. SARS-CoV-2 positivity by PCR was 6.6%, 13.4% and 7.8% in the HCW survey,
293	outpatient survey and household survey, respectively. SARS-CoV-2 positivity by ELISA was 2.3%,
294	5.4% and 3.1% in the HCW survey, outpatient survey and household survey, respectively (Table 2).
295	There was no difference in positivity by sex of the respondent (OR 1.2, [PCR], OR 1.1, [ELISA])
296	(Table 2). Among those for whom PCR testing was completed, positivity differed significantly by
297	age: compared to respondents aged \leq 19 years, respondents within the age groups 20 to 29 and 30 to
298	39 years had higher odds (OR 1.2, 95% CI: 1.12-1.96 and OR 1.4, 95% CI: 1.06-1.93, respectively)
299	of testing SARS-CoV-2 positive by PCR (Table 2).

Table 3. Prevalence and bivariate analysis of SARS-CoV-2 positivity by test modality in six
 districts of Zambia, July 2020

	Tested by PCR (N=4642) *		Tested by ELISA (N=4717)	
	Prevalence n (%)	OR (95%CI)	Prevalence n (%)	OR (95%CI)
Overall	436 (9.4)		177(3.8)	
Sex				
Female	247(8.9)	Ref	105(3.6)	Ref
Male	189(10.2)	1.2(0.96-1.42)	72(4.0)	1.1(0.83-1.53)
Age group				
<19	93(7.6)	Ref	34(3.4)	Ref
20-29	132(10.8)	1.5(1.12-1.96)	46(3.3)	1.0(0.63-1.56)
30-39	96(10.4)	1.4(1.06-1.93)	41(4.2)	1.3(0.79-1.99)
40-49	55(10.0)	1.4(0.96-1.93)	24(4.0)	1.2(0.70-2.05)
50-59	28(7.5)	1.0(0.63-1.52)	16(4.0)	1.2(0.64-2.17)
>60	32(9.3)	1.3(0.81-1.89)	16(4.5)	1.4(0.72-2.44)
Education completed				
None	114(8.1)	Ref	7(3.0)	Ref
Primary	188(10.4)	1.5(0.9-2.53)	50(3.6)	1.2(0.57-2.90)
Secondary	116(10.4)	1.9(1.19-3.26)	83(4.5)	1.5(0.73-3.57)
Higher	18(5.7)	1.9(1.18-3.33)	37(3.0)	1.0(0.46-2.44)

Survey				
	28(6.6)	Ref	12(2.3)	Ref
Healthcare worker				
Outpatient	187(13.4)	2.2(1.47-3.37)	85(5.4)	2.4(1.37-4.73)
Household	221(7.8)	1.2(0.81-1.84)	80(3.1)	1.4(0.76-2.62)
District				
Kabwe	30(4.6)	Ref	14(2.4)	Ref
Lusaka	106(10.8)	2.5(1.70-3.93)	53(4.6)	2.0(1.11-3.69)
Livingstone	108(13.8)	3.4(2.24-5.18)	20(2.4)	1.0(0.50-2.03)
Nakonde	17(5.5)	1.2(0.65-2.22)	48(9.6)	4.3(2.41-8.22)
Ndola	106(10.9)	2.6(1.70-3.93)	26(2.7)	1.1(0.58-2.19)
Solwezi	69(7.3)	1.7(1.07-2.59)	16(2.4)	1.0(0.48-2.08)
Comorbid medical				
condition				
No	354(9.4)	Ref	133(3.5)	Ref
Yes	82(9.2)	0.9(0.71-1.20)	44(4.8)	1.4(0.98-1.97)
HIV Status				
Negative	384(9.1)	Ref	168(3.9)	Ref
Positive	52(12.4)	1.4(1.03-1.91)	9(1.9)	0.5(0.23-0.90)
On ART				
Yes	43(11.8)	Ref	9(2.2)	Ref
No	4(50.0)	7.5(1.72-32.7)	0(0)	0.0
Missing	359		168	
Household contact COVID				
No	432(9.4)	Ref	176(3.8)	Ref
Yes	4(12.5)	1.4(0.41-3.54)	1(3.2)	0.9(0.05-4.02)
Travel				
None	348(9.1)	Ref	152(3.9)	Ref
International	5(16.7)	2.0(0.68-4.87)	2(6.9)	1.8(0.29-6.20)
Domestic	83(10.8)	1.2(0.94-1.56)	23(3.0)	0.8(0.48-1.17)
Visit Health Facility				
No	375(10.2)	Ref	143(3.9)	Ref
Yes	61(6.3)	0.6(0.44-0.78)	34(3.3)	0.8(0.57-1.22)
In-person ¹				
No	313(9.0)	Ref	127(3.6)	Ref
Yes	123(10.6)	1.2(0.96-1.48)	50(4.1)	1.2(0.82-1.60)
Transport	× /		× /	, ,

Walking	251(9.3)	Ref	97(3.6)	Ref
Personal car	45(10.7)	1.2(0.83-1.62)	18(4.0)	1.1(0.64-1.80)
Taxi	45(11.1)	1.2(0.86-1.68)	13(3.5)	1.0(0.51-1.67)
Bike	9(6.6)	0.7(0.32-1.29)	7(5.6)	1.6(0.65-3.24)
Minibus	86(8.8)	0.9(0.73-1.22)	42(4.0)	1.1(0.76-1.58)

302

PLHIV had increased odds of testing positive for SARS-CoV-2 by PCR (OR 1.4, CI: 1.03-1.91) but
had reduced odds of an ELISA-positive test (OR 0.5, 95% CI: 0.23-0.90). Among PLHIV, those not
on ART had increased odds of SARS-CoV-2 infection by PCR (OR: 7.5, 95% CI: 1.72-32.7)) (Table
2).

There was district-by-district variation in SARS-CoV-2 test positivity. Livingstone had the highest test positivity (13.8%) by PCR, while Nakonde had the highest test positivity by ELISA (9.6%) (Table 2). Compared to people who had not received any education, people who had completed secondary and higher education had higher odds of SARS-CoV-2 infection (OR 1.9, 95% CI: 1.19-3.26, OR 1.9, 95% CI: 1.18-3.33, respectively). Excluding HIV as a comorbidity, there was no difference in SARS-CoV-2 test positivity between people who had comorbid medical conditions and those who did not (OR 0.9, 95% CI: 0.71,1.20) (Table 2).

314 Predictors of SAR-CoV-2 positivity among PLHIV

In the multilevel logistic regression model, PLHIV not receiving ART was an independent predictor of SARS-CoV-2 positivity by PCR (aOR 5.78, 95% CI: 1.35-24.76). All the other covariates were insignificant, and none of the covariates were significant in the ELISA analysis (Table 3). There was a similar finding in the ordinary logistic regression model (Table 4).

Table 4. Multilevel multivariate analysis of predictors of SARS-CoV-2 positivity among PLHIV by
 test modality in six districts of Zambia, July 2020

Predictors	PCR Positivity (420) aOR (95%CI)	ELISA positivity (474) aOR (95%CI)
Sex		
Male	1.32(0.70-2.52)	1.62(0.41-6.47)
Any comorbid		
Yes	1.34(0.72-2.49)	3.72(0.94-14.68)
On ART		
No	5.78(1.35-24.76)	5.35(0.54-53.42)
HH contact COVID		
Yes	6.39(0.29-142.79)	NA
In person		
Yes	1.32(0.66-2.62)	0.71(0.13-3.84)
Visit Health facility		
Yes	NA	1.92(0.54-6.85)
Age	NA	0.97(0.92-1.03)

PCR: polymerase chain reaction

ELISA: enzyme-linked immunosorbent assay

aOR: adjusted odds ratio

95%CI: 95%: confidence interval

ART: antiretroviral therapy

In-person attendance at workplace, school or day-care

HH household contact

NA Variables not included in the final model of the respective analysis.

We assumed a random intercept for district and survey type; that is, each of the 6 districts and survey had its unique intercept. In contrast, we assumed fixed effects for all other covariates (that is, an estimated mean effect for the 6 districts). Variables controlled for included age, ART use, sex, visit to a health facility, in-person attendance to a workplace, school, or day care and for the presence of any comorbid medical condition).

Table 5: Predictors of SARS-CoV-2 test positivity by test type, multivariate logistic regression.

324

	PCR Positivity (420) aOR(95%CI)	ELISA positivity (474) aOR(95%CI)
Sex		
Male	1.24(0.65-2.34)	1.58(0.36-6.40)
Age		0.97(0.91-1.02)
Any Comorbid		
Yes	1.32(0.71-2.48)	4.5(1.14-20.37)
On ART		
No	5.24(1.19-22.22)	4.89(0.23-37.94)
HH Contact COVID		
Yes	9.79(0.28-371.89)	NA
In Person		
Yes	1.33(0.66-2.59)	0.87(0.18-3.17)
District		
Kabwe	Ref	
Lusaka	6.49(1.85-31.05)	5.41(0.70-112.35)
Livingstone	9.11(2.86-41.36)	NA
Nakonde	2.3(0.11-19.77)	5.98(0.22-162.36)
Ndola	7.2(2.25-32.89)	5.36(0.77-107.99)
Solwezi	2.55(0.32-16.72)	NA
Visit HF		
Yes	NA	2.08(0.55-7.52)

PCR: polymerase chain reaction

ELISA: enzyme-linked immunosorbent assay

adjusted odds ratio

95%: confidence interval

ART: antiretroviral therapy

In-person attendance at workplace, school or day-care

HH household contact

NA Variables not included in the final model of the respective analysis.

Variables controlled for included age, ART use, sex, visit to a health facility, in-person attendance to a workplace, school, or day care and for the presence of any comorbid medical condition.

327 Clinical features of SAR-CoV-2-positive cases

328 Among participants who tested positive for SARS-CoV-2 by PCR, most were asymptomatic at the

time of testing (74.6% among the HIV negative and 56.0% among PLHIV). However, PLHIV had

- increased odds of being symptomatic compared to HIV-negative participants (OR 2.3, 95% CI 1.3-
- 4.2). PLHIV also more frequently presented with cough, shortness of breath, anorexia, rhinorrhea,
- and abdominal pain compared to HIV-negative SARS-CoV-2 respondents (Table 4).

Table 6: Comparison of symptoms reported by SARS-CoV-2 PCR-positive respondents at
 enrolment by self-reported HIV status in six districts of Zambia, July 2020

	PCR ¹ positive (N=436)			
Symptom	Prevalence, n (%)	OR ²	95% CI ³	
Any symptom				
HIV-negative	98(25.4)	Ref		
PLHIV ⁴	22(44.0)	2.31	1.25, 4.21	
Fever				
HIV-negative	21(5.4)	Ref		
PLHIV	3(6.0)	1.11	0.26, 3.38	
Chills				
HIV-negative	13(3.4)	Ref		
PLHIV	3(6.0)	1.83	0.41, 5.94	
Cough				
HIV-negative	19(4.9)	Ref		
PLHIV	8(16.0)	3.68	1.44, 8.67	
SOB ⁵				
HIV-negative	1(0.3)	Ref		
PLHIV	2(4.0)	16	1.51, 349	
Fatigue				
HIV-negative	11(2.8)	Ref		
PLHIV	2(4.0)	1.42	0.22, 5.50	
Anorexia				
HIV-negative	2(0.5)	Ref	·	
PLHIV	4(8.0)	16.7	7 3.17, 123	
Myalgia				
HIV-negative	9(2.3)	Ref		

³³⁵

PLHIV 1(2.0) 0.85 0.05, 4.69 Arthralgias I I HIV-negative 8(2.1) Ref I PLHIV 1(2.0) 0.96 0.05, 5.42 Rhinorrea I I HIV-negative 19(4.9) Ref I PLHIV 7(14.0) 3.14 1.17, 7.62 Wheezing I I I HIV-negative 1(0.3) Ref I PLHIV 1(2.0) 7.86 0.31, 201 HIV-negative 3(0.8) Ref I PLHIV 1(2.0) 2.61 0.13, 20.8 Abdominal pain I I I HIV-negative 3(0.8) Ref I PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea I I I HIV-negative 3(0.8) Ref I PLHIV 2(4.0) 5.32 0.69, 32.9 HIV-negative 9(2.3)			1	
HIV-negative 8(2.1) Ref — PLHIV 1(2.0) 0.96 0.05, 5.42 Rhinorrea I I HIV-negative 19(4.9) Ref — PLHIV 7(14.0) 3.14 1.17, 7.62 Wheezing I I IIIV, 7.62 Wheezing 1(0.3) Ref — PLHIV 1(2.0) 7.86 0.31, 201 Altered taste I I IIIV-negative HIV-negative 3(0.8) Ref — PLHIV 1(2.0) 2.61 0.13, 20.8 Abdominal pain I IIIV-negative 3(0.8) Ref — PLHIV 10(2.6) Ref IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	PLHIV	1(2.0)	0.85	0.05, 4.69
PLHIV 1(2.0) 0.96 0.05, 5.42 Rhinorrea I I HIV-negative 19(4.9) Ref — PLHIV 7(14.0) 3.14 1.17, 7.62 Wheezing I I I I HIV-negative 1(0.3) Ref — PLHIV 1(2.0) 7.86 0.31, 201 Altered taste I I I HIV-negative 3(0.8) Ref — PLHIV 1(2.0) 2.61 0.13, 20.8 Abdominal pain I I I HIV-negative 10(2.6) Ref — PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea I I I HIV-negative 3(0.8) Ref — PLHIV 2(4.0) 5.32 0.69, 32.9 Chest pain I I I HIV-negative 9(2.3) Ref — PLHIV	Arthralgias			
Rhinorrea Image: Market instant instan	HIV-negative	8(2.1)	Ref	
HIV-negative 19(4.9) Ref PLHIV 7(14.0) 3.14 1.17, 7.62 Wheezing 1(0.3) Ref HIV-negative 1(0.3) Ref PLHIV 1(2.0) 7.86 0.31, 201 Altered taste HIV-negative 3(0.8) Ref PLHIV 1(2.0) 2.61 0.13, 20.8 Abdominal pain HIV-negative 10(2.6) Ref PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea HIV-negative 3(0.8) Ref PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea PLHIV 2(4.0) 5.32 0.69, 32.9 Chest pain HIV-negative 9(2.3) Ref PLHIV 2(4.0) 1.75 0.26, 7.02 Headache <td>PLHIV</td> <td>1(2.0)</td> <td>0.96</td> <td>0.05, 5.42</td>	PLHIV	1(2.0)	0.96	0.05, 5.42
PLHIV 7(14.0) 3.14 1.17, 7.62 Wheezing I I I HIV-negative 1(0.3) Ref — PLHIV 1(2.0) 7.86 0.31, 201 Altered taste I I HIV-negative 3(0.8) Ref — PLHIV 1(2.0) 2.61 0.13, 20.8 Abdominal pain I I I HIV-negative 10(2.6) Ref — PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea I I I HIV-negative 3(0.8) Ref — PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea I I I HIV-negative 3(0.8) Ref — PLHIV 2(4.0) 5.32 0.69, 32.9 Chest pain I I I I HIV-negative 9(2.3) Ref — PLHIV 2(4.0) 1.75 0.26, 7.02 Headache I I	Rhinorrea			
Wheezing Image of the table of tabl	HIV-negative	19(4.9)	Ref	_
HIV-negative 1(0.3) Ref — PLHIV 1(2.0) 7.86 0.31, 201 Altered taste ////////////////////////////////////	PLHIV	7(14.0)	3.14	1.17, 7.62
PLHIV 1(2.0) 7.86 0.31, 201 Altered taste - - HIV-negative 3(0.8) Ref - PLHIV 1(2.0) 2.61 0.13, 20.8 Abdominal pain - - HIV-negative 10(2.6) Ref - PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea - - - HIV-negative 3(0.8) Ref - PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea - - - HIV-negative 3(0.8) Ref - PLHIV 2(4.0) 5.32 0.69, 32.9 Chest pain - - - HIV-negative 9(2.3) Ref - PLHIV 2(4.0) 1.75 0.26, 7.02 Headache - - - HIV-negative 44(11.4) Ref - PLHIV 5(10.0) 0.86 0.29, 2.11 Any other ⁶ - - -	Wheezing			
Altered taste Image: Constraint of the symbol of the s	HIV-negative	1(0.3)	Ref	—
HIV-negative3(0.8)Ref—PLHIV1(2.0)2.610.13, 20.8Abdominal pain2.610.13, 20.8HIV-negative10(2.6)Ref—PLHIV5(10.0)4.181.26, 12.3DiarrhoeaHIV-negative3(0.8)Ref—PLHIV2(4.0)5.320.69, 32.9Chest painHIV-negative9(2.3)Ref—PLHIV2(4.0)1.750.26, 7.02HeadacheHIV-negative44(11.4)Ref—PLHIV5(10.0)0.860.29, 2.11Any other ⁶ HIV-negative15(3.9)Ref-	PLHIV	PLHIV 1(2.0)		
PLHIV 1(2.0) 2.61 0.13, 20.8 Abdominal pain HIV-negative 10(2.6) Ref PLHIV 5(10.0) 4.18 1.26, 12.3 Diarrhoea HIV-negative 3(0.8) Ref PLHIV 2(4.0) 5.32 0.69, 32.9 Chest pain HIV-negative 9(2.3) Ref PLHIV 2(4.0) 1.75 0.26, 7.02 Headache HIV-negative 9(2.3) Ref PLHIV 2(4.0) 1.75 0.26, 7.02 Headache HIV-negative 44(11.4) Ref PLHIV 5(10.0) 0.86 0.29, 2.11 Any other ⁶ HIV-negative 15(3.9) Ref	Altered taste			
Abdominal pain Image: Market interval and interval	HIV-negative	3(0.8)	Ref	—
HIV-negative10(2.6)Ref—PLHIV5(10.0)4.181.26, 12.3DiarrhoeaHIV-negative3(0.8)Ref—PLHIV2(4.0)5.320.69, 32.9Chest painHIV-negative9(2.3)Ref—PLHIV2(4.0)1.750.26, 7.02HeadacheHIV-negative44(11.4)Ref—PLHIV5(10.0)0.860.29, 2.11Any other ⁶ HIV-negative15(3.9)Ref—	PLHIV	1(2.0)	2.61	0.13, 20.8
PLHIV5(10.0)4.181.26, 12.3DiarrhoeaHIV-negative3(0.8)RefPLHIV2(4.0)5.320.69, 32.9Chest painHIV-negative9(2.3)RefPLHIV2(4.0)1.750.26, 7.02HeadacheHIV-negative44(11.4)RefPLHIV5(10.0)0.860.29, 2.11Any other ⁶ HIV-negative15(3.9)Ref	Abdominal pain			
Diarrhoea Image: Constraint of the sector of t	HIV-negative	10(2.6)	Ref	—
HIV-negative3(0.8)Ref—PLHIV2(4.0)5.320.69, 32.9Chest painIIHIV-negative9(2.3)Ref—PLHIV2(4.0)1.750.26, 7.02HeadacheIIHIV-negative44(11.4)Ref—PLHIV5(10.0)0.860.29, 2.11Any other ⁶ IIHIV-negative15(3.9)Ref—	PLHIV	5(10.0)	4.18	1.26, 12.3
PLHIV 2(4.0) 5.32 0.69, 32.9 Chest pain - - HIV-negative 9(2.3) Ref - PLHIV 2(4.0) 1.75 0.26, 7.02 Headache - - HIV-negative 44(11.4) Ref - PLHIV 5(10.0) 0.86 0.29, 2.11 Any other ⁶ - - - HIV-negative 15(3.9) Ref -	Diarrhoea			
Chest pain Image: Market of the second	HIV-negative	3(0.8)	Ref	—
HIV-negative9(2.3)Ref—PLHIV2(4.0)1.750.26, 7.02HeadacheHIV-negative44(11.4)Ref—PLHIV5(10.0)0.860.29, 2.11Any other ⁶ HIV-negative15(3.9)Ref—	PLHIV	2(4.0)	5.32	0.69, 32.9
PLHIV2(4.0)1.750.26, 7.02HeadacheHIV-negative44(11.4)Ref—PLHIV5(10.0)0.860.29, 2.11Any other ⁶ HIV-negative15(3.9)Ref—	Chest pain			
Headache Image: marked state sta	HIV-negative	9(2.3)	Ref	—
HIV-negative 44(11.4) Ref — PLHIV 5(10.0) 0.86 0.29, 2.11 Any other ⁶ HIV-negative 15(3.9) Ref —	PLHIV	2(4.0)	1.75	0.26, 7.02
PLHIV 5(10.0) 0.86 0.29, 2.11 Any other ⁶ HIV-negative 15(3.9) Ref —	Headache			
Any other6Image: Any other6HIV-negative15(3.9)Ref—	HIV-negative	44(11.4)	Ref	_
HIV-negative 15(3.9) Ref —	PLHIV	5(10.0)	0.86	0.29, 2.11
	Any other ⁶			
PLHIV 5(10.0) 2.75 0.86, 7.48	HIV-negative	15(3.9)	Ref	
	PLHIV	5(10.0)	2.75	0.86, 7.48

¹PCR: polymerase chain reaction ² OR: odds ratio

³95% confidence interval

⁴PLHIV: people living with HIV.

⁵ SOB: shortness of breath.

⁶Any other symptom not listed

338 Discussion

The aim of this study was to compare the SARS-CoV-2 test positivity, clinical presentation, and predictors of SARS-CoV-2 positivity between PLHIV and people who are HIV negative in six districts of Zambia. Our findings showed that among respondents to surveys administered during the early COVID-19 pandemic, PLHIV had higher odds of testing positive for SARS-CoV-2 by PCR than HIV-negative respondents, and at the time of testing for SARS-CoV-2 infection, PLHIV who tested PCR-positive were more frequently symptomatic than participants who were HIV negative. Among PLHIV, not being on ART was an independent predictor of SARS-CoV-2 PCR positivity.

PLHIV had higher odds of testing positive for SARS-CoV-2 by PCR than HIV-negative respondents. 346 In this study, PLHIV were older and had more comorbidities than the HIV-negative participants; this 347 348 could have affected our findings, as both increasing age and a greater number of comorbidities have been shown to increase the risk of SARS-CoV-2 infection (3–5) Additionally, early in the first wave, 349 PLHIV may have had an additional risk of exposure to SARS-CoV-2 due to more frequent hospital 350 351 visits for medical review and drug collection. This finding is consistent with findings from a large, pooled analysis of 22 studies from across the world from early 2020 through 2021 that showed that 352 PLHIV had 24% higher odds of SARS-CoV-2 infection than their HIV-negative counterparts 353 (30,41,42). Underlying socioeconomic disparities in PLHIV have been shown to increase exposure to 354 SARS-CoV-2 (43). Among PLHIV, not being on ART was an independent predictor of SARS-CoV-2 355 PCR positivity. Most studies performed on HIV and SARS-CoV-2 coinfection were inconclusive 356 about the effect of ART, as most PLHIV in these studies were on suppressive ART (42). PLHIV who 357 have not achieved viral suppression through ART may have a compromised immune system that 358 leaves them vulnerable to opportunistic infections (44). 359

In the bivariate analysis, there were reduced odds of a positive ELISA test among PLHIV compared
to the HIV-negative respondents. As ELISA detects the body's humoral response to SARS-CoV-2

infection, factors that affect the body's immune system may affect the reliability of this test. HIV 362 affects CD4+ T cells, which play a key role in orchestrating the immune system (9). As such, PLHIV 363 may have a delayed or decreased response in producing antibodies to SARS-CoV-2 after a natural 364 infection. Several seroprevalence surveys of SARS-CoV-2 antibody and HIV testing have shown that 365 PLHIV are less likely to be seropositive than HIV-uninfected individuals (45–47). In these surveys, 366 high HIV viral load, low host CD4 count or not yet on ART was associated with poorer antibody 367 368 response to SARS-CoV-2 infection (44,46,47). Further research may be required to verify this finding among PLHIV in Zambia. 369

Overall, PLHIV were more likely to present with a symptomatic SARS-CoV-2 infection at the time 370 of testing. Additionally, cough, shortness of breath, anorexia, rhinorrhea, and abdominal pain were 371 more likely in PLHIV. These findings suggest that at the time of enrolment, PLHIV were more likely 372 to have a symptomatic SARS-CoV-2 infection than HIV-negative people. Our findings are consistent 373 with a review of 22 studies that included over 20 million participants across North America, Africa, 374 Europe, and Asia that showed an increased risk of severe outcomes in PLHIV (31,48), although most 375 PLHIV in these studies had been on suppressive ART. A study by the WHO showed that PLHIV were 376 at increased risk of severe or critical disease at hospital admission (aOR 1.1, 95% CI 1.0-1.1) 377 378 compared to HIV-negative individuals (48).

Our study had several limitations. The timing of the study at the beginning of the first wave in Zambia 379 380 could have biased positive results to those respondents more linked to international or domestic travel. A past medical history of underlying conditions such as HIV was self-reported. As we merged data 381 from three surveys, some study-specific variables had much missingness in the combined data set and 382 therefore could not be analysed further. This resulted in fewer explanatory variables in our analysis. 383 Additionally, PCR positivity can be long-lasting, especially among people who are 384 immunocompromised. As such, people who are PCR positive may be weeks away from the initial 385 infection. 386

387 Despite these limitations, we believe that our findings are valid due to the large sample size, inclusion 388 of study participants across different sociodemographic characteristics, and geographic settings and 389 due to consistency in the findings of this study with other local and international studies.

390 Conclusion

These findings suggest that at the time of enrolment in the study, during the first COVID-19 wave in Zambia, PLHIV were at an increased risk of SARS-CoV-2 infection, as evidenced by PCR, but were less likely to have had a prior infection, as evidenced by ELISA. Among the infected individuals, PLHIV were more likely to be symptomatic. Among PLHIV, not being on ART was independently associated with an increased risk of SARS-CoV-2 infection. Interventions focusing on ensuring early access to COVID-19 vaccinations, testing and ART might reduce COVID-19 morbidity among PLHIV.

399 Acknowledgements

400 We thank the Ministry of Health, Zambia, for providing SARS-CoV-2 prevalence data in Zambia.

402 References

- ZNPHI A Centre of Excellence in Public Health Security for a Healthy Zambia [Internet]. [cited
 2023 Jan 23]. Available from: http://znphi.co.zm/
- Chipimo PJ, Barradas DT, Kayeyi N, Zulu PM, Muzala K, Mazaba ML, et al. First 100 Persons with
 COVID-19 Zambia, March 18–April 28, 2020. MMWR Morb Mortal Wkly Rep.
 2020;69(42):1547–8.
- Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of
 Coronavirus Disease 2019 in China. New England Journal of Medicine [Internet]. 2020 Apr 30 [cited
 2021 Jan 18];382(18):1708–20. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2002032
- 4. Sachs JD, Horton R, Bagenal J, Ben Amor Y, Karadag Caman O, Lafortune G. The Lancet COVID19 Commission. Lancet [Internet]. 2020 Aug 15 [cited 2023 Jan 23];396(10249):454–5. Available
 from: https://pubmed.ncbi.nlm.nih.gov/32653081/
- 414 5. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-

infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Annals of

416 Oncology [Internet]. 2020 Jul 1 [cited 2021 Feb 16];31(7):894–901. Available

- 417 from:/pmc/articles/PMC7270947/
- 418 6. Zambia | UNAIDS [Internet]. [cited 2021 May 20]. Available from:
- 419 https://www.unaids.org/en/regionscountries/countries/zambia
- 420 7. Nomah DK, Reyes-Urueña J, Llibre JM, Ambrosioni J, Ganem FS, Miró JM, et al. HIV and SARS-
- 421 CoV-2 Coinfection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and
- 422 Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. Curr HIV/AIDS
- 423 Rep [Internet]. 2021 Dec 1 [cited 2022 Jul 29];18(6):518. Available from:/pmc/articles/PMC8661831/
- 424 8. Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, et al. HIV and coinfections. Immunol
- 425 Rev [Internet]. 2013 Jul [cited 2023 Jan 23];254(1):114–42. Available from:
- 426 https://pubmed.ncbi.nlm.nih.gov/23772618/

- Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, et al. T-cell exhaustion in HIV infection
 [Internet]. Vol. 292, Immunological Reviews. Blackwell Publishing Ltd; 2019 [cited 2021 Feb 16]. p.
 149–63. Available from:/pmc/articles/PMC7003858/
- 430 10. He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, et al. Effects of severe acute respiratory
- 431 syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets.
- 432 International Journal of Infectious Diseases [Internet]. 2005 Nov [cited 2021 Feb 16];9(6):323–30.

433 Available from: https://pubmed.ncbi.nlm.nih.gov/16095942/

- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of
 severe and moderate coronavirus disease 2019. Journal of Clinical Investigation [Internet]. 2020 May
 [cited 2021 Feb 16];130(5):2620–9. Available from: https://doi.org/10.1172/JCI137244.
- 437 12. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients
 438 with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases [Internet]. 2020
- 439 Aug 1 [cited 2021 Feb 16];71(15):762–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32161940/
- 13. SeyedAlinaghi SA, Karimi A, MohsseniPour M, Barzegary A, Mirghaderi SP, Fakhfouri A, et al. The
- 441 clinical outcomes of COVID-19 in HIV-positive patients: A systematic review of current evidence.
- Immun Inflamm Dis [Internet]. 2021 Dec 1 [cited 2023 Aug 31];9(4):1160. Available
- 443 from:/pmc/articles/PMC8426924/

Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA
dependent RNA polymerase (RdRp): A molecular docking study. Life Sci [Internet]. 2020 Jul 15
[cited 2021 Feb 16];253:117592. Available from:/pmc/articles/PMC7102646/

- 447 15. Amo J del, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and Severity of
- 448 COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. https://doi.org/107326/M20-
- 449 3689 [Internet]. 2020 Jun 26 [cited 2021 Oct 26];173(7):536–41. Available from:
- 450 https://www.acpjournals.org/doi/abs/10.7326/M20-3689

- 451 16. George S, McGrath N, Oni T. The association between a detectable HIV viral load and
- 452 noncommunicable diseases comorbidity in HIV positive adults on antiretroviral therapy in Western
- 453 Cape, South Africa. BMC Infect Dis [Internet]. 2019 Apr 27 [cited 2021 Apr 23];19(1). Available
 454 from: https://pubmed.ncbi.nlm.nih.gov/31029087/
- 455 17. Byrd KM, Beckwith CG, Garland JM, Johnson JE, Aung S, Cu-Uvin S, et al. SARS-CoV-2 and HIV
 456 coinfection: clinical experience from Rhode Island, United States. 2020 [cited 2021 Feb 8]; Available
 457 from: http://onlinelibrary.wiley.com/doi/10.1002/jia2.25573/full
- 458 18. Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes
- 459 Among HIV-Positive Patients Hospitalised With COVID-19 [Internet]. 2020 [cited 2021 Feb 8].
- 460 Available from: http://links.lww.com/QAI/B494
- Calza L, Bon I, Tadolini M, Borderi M, Colangeli V, Badia L, et al. COVID-19 in patients with HIV1 infection: a single-centre experience in northern Italy. Infection [Internet]. 2020 [cited 2021 Feb
 8];1:1. Available from:/pmc/articles/PMC7397968/?report=abstract
- 464 20. Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living
 465 with human immunodeficiency virus: a case series of 33 patients. Infection [Internet]. 2020 Oct 1
 466 [cited 2021 Feb 8];48(5):681–6. Available from:/pmc/articles/PMC7211976/?report=abstract
- 467 21. Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al. Epidemiology

and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci

- 469 Rep [Internet]. 2021 Dec 1 [cited 2021 Jul 5];11(1). Available from:
- 470 https://pubmed.ncbi.nlm.nih.gov/33737527/

- 471 22. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and
 472 COVID-19 death: a population-based cohort analysis of UK primary care data and linked national
- death registrations within the OpenSAFELY platform. Lancet HIV. 2021 Jan 1;8(1):e24–32.
- 474 23. Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients
 475 with HIV: A multicentre research network study. AIDS. 2020 Nov 1;34(13):F3–8.

476	24.	Miyashita H, Kuno T. Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV
477		infection in New York City. HIV Med. 2021 Jan 1;22(1):e1-2.

- 478 25. Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living
 479 with human immunodeficiency virus: a case series of 33 patients. Infection. 2020 Oct 1;48(5):681–6.
- 480 26. Altuntas Aydin O, Kumbasar Karaosmanoglu H, Kart Yasar K. HIV/SARS-CoV-2 coinfected patients
 481 in Istanbul, Turkey. J Med Virol. 2020 Nov 1;92(11):2288–90.
- 482 27. Ho HE, Peluso MJ, Margus C, Matias Lopes JP, He C, Gaisa MM, et al. Clinical outcomes and
 483 immunologic characteristics of coronavirus disease 2019 in people with human immunodeficiency
 484 virus. Journal of Infectious Diseases. 2021 Feb 1;223(3):403–8.
- Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019
 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for
 Disease Control and Prevention [Internet]. Vol. 323, JAMA Journal of the American Medical
 Association. American Medical Association; 2020 [cited 2021 Jan 23]. p. 1239–42. Available from:
- 489 https://jamanetwork.com/
- 490 29. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clinical
 491 Infectious Diseases [Internet]. 2021 Jan 27 [cited 2021 Feb 16];72(2):340–50. Available
 492 from:/pmc/articles/PMC7337668/

493 30. Hsiao M, Davies MA, Kalk E, Hardie D, Naidoo M, Centner C, et al. SARS-CoV-2

494 SEROPREVALENCE IN THE CAPE TOWN METROPOLITAN SUB-DISTRICTS AFTER THE

- 495 PEAK OF INFECTIONS [Internet]. [cited 2021 Feb 8]. Available from: www.nicd.ac.za
- 496 31. Cohen C, Kleynhans J, von Gottberg A, McMorrow ML, Wolter N, Bhiman JN, et al. SARS-CoV-2
 497 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C
- 498 cohort study, South Africa, 2020-21. Lancet Infect Dis [Internet]. 2022 Jun 1 [cited 2023 Jan
- 499 23];22(6):821–34. Available from: http://www.thelancet.com/article/S147330992200069X/fulltext

- 500 32. Chanda D. COVID-19 Severity and COVID-19–Associated Deaths Among Hospitalised Patients with
 501 HIV Infection Zambia, March–December 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2021
 502 Jun 4 [cited 2021 Jul 12];70(22):807–10. Available from:
- 503 https://www.cdc.gov/mmwr/volumes/70/wr/mm7022a2.htm
- Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and
 risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital:
 analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022 Jul
 1;9(7):e486–95.
- 34. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière V, et al. Covid-19
 vaccine immunogenicity in people living with HIV-1. Vaccine [Internet]. 2022 Jun 6 [cited 2023 Jan
 23];40(26):3633. Available from:/pmc/articles/PMC9069249/
- 511 35. Wolter N, Tempia S, von Gottberg A, Bhiman JN, Walaza S, Kleynhans J, et al. Seroprevalence of
- 512 Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human
- 513 Immunodeficiency Virus–Infected and Uninfected Persons: A Cross-Sectional Household Survey.
- 514 Clinical Infectious Diseases [Internet]. 2022 Aug 24 [cited 2023 Jan 23];75(1):e57–68. Available
- from: https://academic.oup.com/cid/article/75/1/e57/6546682
- 516 36. Shanaube K, Schaap A, Klinkenberg E, Floyd S, Bwalya J, Cheeba M, et al. SARS-CoV-2
- 517 seroprevalence and associated risk factors in periurban Zambia: a population-based study.
- 518 International Journal of Infectious Diseases [Internet]. 2022 May 1 [cited 2023 Jan 23];118:256.
- 519 Available from:/pmc/articles/PMC8925090/
- 37. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière V, et al. Covid-19
 vaccine immunogenicity in people living with HIV-1. Vaccine [Internet]. 2022 Jun 6 [cited 2023 Jan
 23];40(26):3633. Available from:/pmc/articles/PMC9069249/
- 38. SARS-CoV-2 Fluorescent PCR Kit For Use under the Emergency Use Authorisation Only For In
 vitro Diagnostic (IVD) Use RX Only Instructions for Use, Revision 3.1 SARS-CoV-2 Fluorescent
- 525 PCR Kit P/N: BUSGN7101109 32 tests SARS-CoV-2 Fluorescent PCR Kit P/N: BUSGN7102109 64

526		tests SARS-CoV-2 Fluorescent PCR Kit P/N: BUSGN7103109 96 tests Nucleic Acid Extraction Kit,
527		Manual Version P/N: GN7102903 48 tests Nucleic Acid Extraction Kit, Fast. 2020;
528	39.	Sample to Insight - QIAGEN [Internet]. [cited 2023 Sep 15]. Available from:
529		https://www.qiagen.com/us
530	40.	R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for
531		Statistical Computing, Vienna, Austria. 2018;
532	41.	Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. Clinical Features and
533		Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clinical Infectious
534		Diseases [Internet]. 2020 Nov 19 [cited 2023 Jan 24];71(16):2276–8. Available from:
535		https://academic.oup.com/cid/article/71/16/2276/5837155
536	42.	Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al. Epidemiology
537		and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci
538		Rep [Internet]. 2021 Dec 1 [cited 2023 Jan 23];11(1). Available from:
539		https://pubmed.ncbi.nlm.nih.gov/33737527/
540	43.	Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and
541		COVID-19 death: a population-based cohort analysis of UK primary care data and linked national
542		death registrations within the OpenSAFELY platform. Lancet HIV [Internet]. 2021 Jan 1 [cited 2023
543		Jan 23];8(1):e24–32. Available from: https://pubmed.ncbi.nlm.nih.gov/33316211/
544	44.	Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and
545		risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital:
546		analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022 Jul
547		1;9(7):e486–95.


548 45. Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and
549 risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital:

- analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022 Jul
 1;9(7):e486–95.
- 46. Wolter N, Tempia S, von Gottberg A, Bhiman JN, Walaza S, Kleynhans J, et al. Seroprevalence of
 Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human
 Immunodeficiency Virus-Infected and Uninfected Persons: A Cross-Sectional Household Survey.
- 555 Clin Infect Dis [Internet]. 2022 Jul 1 [cited 2023 Jan 24];75(1):e57–68. Available from:
- 556 https://pubmed.ncbi.nlm.nih.gov/35271693/
- 47. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière V, et al. Covid-19
 vaccine immunogenicity in people living with HIV-1. Vaccine [Internet]. 2022 Jun 6 [cited 2023 Jan
 24];40(26):3633. Available from:/pmc/articles/PMC9069249/
- 560 48. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalised with
 561 suspected or confirmed SARS-CoV-2 infection [Internet]. [cited 2023 Jan 24]. Available from:
 562 https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1

563


565 Tables and Figures

- **Figure 1A**: Summary of the study participant recruitment algorithm by study type
- Figure 1B: Outline of the algorithm of the selection of study participants into the different arms ofthe study
- Table 1: Demographic characteristics of study participants tested for SARS-CoV-2 infection, 6
 districts, Zambia, July 2020
- Table 2: Demographic characteristics of respondents stratified by HIV status and SARS-CoV-2 test
 type.
- Table 3: Prevalence and bivariate analysis of SARS-CoV-2 positivity by test modality in six
 districts of Zambia, July 2020
- Table 4: Multilevel multivariate analysis of predictors of SARS-CoV-2 positivity among PLHIV by
 test modality in six districts of Zambia, July 2020
- 577 Table 5: Predictors of SARS-CoV-2 test positivity by test type, multivariate logistic regression
- **Table 6:** Comparison of symptoms reported by SARS-CoV-2 PCR-positive respondents at
- enrolment by self-reported HIV status in six districts of Zambia, July 2020



*11 Entries in the data set had a missing survey-type variable

Figure1A



** PCR: polymerase chain reaction, *PLHIV: people living with HIV, * ELISA: enzyme-linked immunosorbent assay

Figure1B